Elekta AB Class B

Elekta AB Class B

EKTAF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.35B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Elekta AB Class BElekta AB Class B-64.43.95%-7%0.11.8

Earnings Call Q3 2026

March 5, 2026 - AI Summary

Q3 performance: “solid” but held back by FX and tariffs - Net sales +2% YoY (Solutions +1%, Service +3%). - Gross margin 38.3% (+120 bps YoY), supported by product launches (Elekta Evo, Elekta ONE) and pricing/mix tailwinds, but with major headwinds: - Tariffs: -100 bps - FX: -130 bps (also drove reported growth down) - Reported EBIT margin 11.9% (+20 bps YoY), helped by improved gross margin and cost reductions, but impacted by accounting dynamics (lower capitalization, higher amortization). - Reported EBIT included restructuring charge of ~SEK 417m (items affecting comparability).
Orders/book-to-bill: healthy demand trend, China rebounding; US improving after Evo approval - Book-to-bill (Q3): 1.17 (vs 1.15 last year); rolling 12 months: 1.09 (healthy though management wants it higher). - Organic growth ~2% YoY, with continued momentum in Europe. - China returned to growth after 2 years of anticorruption-driven softness; management expects ~10% double-digit order and revenue growth in China in H2 (~2H “around 10%”). - US is a key focus: management emphasized substantial double-digit order growth YTD, driven by Evo approval (announced Jan 16) and conversion/upgrading of backlog (and also upgrading to Iris); market remains challenged due to depleted backlog reflected in revenue timing.
FX/tariff drag: explicitly large on reported numbers - Management quantified FX impact on Q3 net sales as >SEK 500m negative, described as corresponding to ~-12% growth on reported terms (currency-driven translation + cost-currency effects). - They expect continued tariff impact in Q4 (and reiterated guidance unchanged otherwise).

Exclusive for Stockcircle Pro members

Sign upSign Up
$5.23

Current Fair Value

14.6% downside

Overvalued by 14.6% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$2.35 Billion
Enterprise Value$13.84 Billion
Annual dividend$0.26
Dividend yield3.95%
Earnings per Share$-1.38
Beta0.96
Outstanding Shares382,083,120

Return

Return on Equity-7.48%ROE
Return on Assets-2.12%
Return on Invested Capital5.69%

Valuation & Multiples

P/E Ratio-64.37P/E Ratio
PEG-44.15PEG
Price to Sales0.14Price to Sales
Price to Book Ratio0.32Price to Book Ratio
Enterprise Value to Revenue0.84
Enterprise Value to EBIT19.87
Enterprise Value to Net Income-25
Total Debt to Enterprise1
Debt to Equity1.83Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 27, 2026
EPS
$0.07
Est. $0.05
Revenue
$370.22 M
Est. $380.56 M

Next Earnings Call

Expected Date
November 25, 2026
EPS Estimate
$0.09
Consensus analyst estimate
Revenue Estimate
$425.02 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Elekta AB

4,102 employees
CEO: Gustaf Salford

Elekta AB is a medical technology company. It engages in the provision of clinical solutions for the treatment of cancers and brain disorders. The firm's products and solutions include radiotherapy, stereotactic radiosurgery, oncology in...

Elekta AB Class B Insider Information FAQ

In the latest 13F quarter on Stockcircle, 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.